iFR Physiology
Image-guided therapy

iFR

Contact salesFind support

Be confident in treatment and deferral decisions with Philips iFR

iFR is in a class of its own and is the leading hyperemia-free physiologic index for measuring pressure in diagnostic and interventional procedures. Only offered by Philips, iFR Co-registration maps the physiologic measurements directly onto the angiogram enabling more complete procedural guidance. No other resting index has an ESC and ACC/AHA/SCAI Class IA recommendation based on the high level of clinical evidence for its accuracy. Philips iFR is the Gold Standard.1,2

Demonstrated results

  1. 1 in 4

    with angiographically successful PCI left the cath lab with residual ischemia

    1 in 4

    with angiographically successful PCI left the cath lab with residual ischemia

    (defined as iFR <0.90, residual DS < 50% in any treated lesion).3​

  2. 68%

    relative reduction in clinical events

    68%

    relative reduction in clinical events

    at one year follow-up among patients achieving post-PCI iFR ≥ 0.95 (p-value=0.04).4​

  3. 81.6%

    of the patients with residual ischemia

    81.6%

    of the patients with residual ischemia

    were caused by an untreated angiographically inapparent physiologically focal stenosis (≤ 15 mm).3​

  4. $1024

    on average saved with iFR compared to FFR

    $1024

    on average saved with iFR compared to FFR

    as found by iFR Swedeheart.5

Discover how ACT1 ACT2 guides clinical decisions
The ACT1 ACT2 workflow uses Philips iFR to elevate physiologic decision-making, allowing physicians to determine whether and where to treat and confirm treatment decisions. Learn more about how Philips iFR can help you leave no ischemia behind.
Read more
Discover how ACT PCI guides clinical decisions
Only iFR has Co-registration for advanced physiologic guidance
Map iFR values directly onto the angiogram so you can see which parts of a vessel are causing ischemia. With iFR Co-registration there is no need for hyperemic drugs. You can automatically co-register values in seconds onto the angiogram.
- Better discern focal, serial or diffuse disease6
- Determine precise lesion severity and location7,8
- Make length measurements without a cumbersome pullback device6
- Estimate the physiologic impact of a virtual stent6
iFR Co-registration is available on the new Philips IntraSight interventional applications platform and as an upgrade to the Core systems.
iFR Co-registration
iFR Pullback technology7
iFR Pullback technology reveals the physiologic profile of the entire vessel, so when you encounter diffuse disease or serial lesions you can make informed treatment decisions.
Provides beat-by-beat iFR pressure measurements across the entire vessel, artery-by-artery
Establishes the physiological significance of each vessel and/or individual lesion (focal or diffuse)
Provides a clear view of the functional gain
iFR pullback technology

Image gallery

  • iFR pullback technology
    iFR pullback technology reveals the physiologic profile of the entire vessel, so when you encounter diffuse disease or serial lesions you can make informed treatment decisions
  • iFR focal disease
    iFR Co-registration graphically displays the iFR drop along the angiogram, highlighting which portion of the vessel is ischemic.
  • iFR diffuse disease
    iFR Co-registration graphically displays the iFR drop along the angiogram, highlighting which portion of the vessel is ischemic.
  • Philips FFR
    Philips physiology wires enable measurement of both FFR and iFR, both supported by key industry guidelines including ESC Class IA designation.5
  • iFR and IVUS Tri-registration
    Obtain easy length measurements that combine IVUS and iFR information with the angiogram to help determine if a stent will meet the procedural objectives
  • Class IA recommendation award

Documentation

iFR and iFR brochure
PDF|(1.91 MB)
iFR Co-registration workflow quick guide
PDF|(554.25 KB)
SyncVision brochure
PDF|(5.79 MB)
Footnotes
  1. Neumann, F-J et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal (2019) 40, 87–165.
  2. Lawton J. et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization. JACC. 2022;79(2):e21-e129.
  3. Jeremias A et al. Blinded physiological assessment of residual ischemia after successful angiographic percutaneous coronary Intervention: The DEFINE PCI Study. JACC Cardiovasc Interv. 2019 Oct 28;12(20):1991-2001.
  4. Patel et al. 1-Year Outcomes of Blinded Physiological Assessment of Residual Ischemia After Successful PCI. J Am Coll Cardiol Intv 2022;15:52–6.
  5. Berntorp et al. Instantaneous wave-free ratio compared with fractional flow reserve in PCI: A cost-minimization analysis. Int J Cardiol 2021 1;344:54-59.
  6. Nijjer SS, et al. Pre-angioplasty instantaneous wave-free ratio pullback provides virtual intervention and predicts hemodynamic outcome for serial lesions and diffuse coronary re-angioplasty instantaneous wave-free ratio pullback provides virtual intervention and predicts hemodynamic outcome for serial lesions and diffuse coronary artery disease. JACC Cardiovasc Interv. 2014;7(12):1386-96.
  7. Co-registration operator's manual D001336104_A_300010660481
  8. Data on file at Philips Syncvision co-registration validation report D001370468_B
  9. Davies JE, et al., Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI. N Engl J Med. 2017 24-1834
  10. Gotberg M, et al. iFR-SWEDEHEART Investigators. Instantaneous Wave-free Ratio versus Fractional Flow Reserve to Guide PCI. N Engl J Med. 2017 May 11;376(19):1813-1823.
  11. Data on file at Philips D000410086_A, D000485394_A
Disclaimer
Results are specific to the institution where they were obtained and may not reflect the results achievable at other institutions. Results in other cases may vary.